Dihydroberberine for Blood Sugar Regulation

Research suggests that dihydroberberine (DHB) may support blood sugar regulation primarily by improving upon berberine's well-documented but limited oral bioavailability, with preclinical studies indicating it is absorbed several times more efficiently than standard berberine and may act through multiple mechanisms including AMPK activation, mitochondrial modulation, and glucokinase-stimulated insulin secretion. The available evidence base consists largely of cell culture studies, rodent experiments, one small pilot randomized controlled trial in five healthy men, and several narrative reviews, all of which directionally support DHB's potential metabolic benefits, though none of this constitutes robust human clinical evidence. Studies indicate that DHB's enhanced absorption may translate to meaningful reductions in blood glucose, improved insulin sensitivity, and favorable lipid changes in animal models of obesity and type 2 diabetes, and one mechanism study further clarified that gut bacteria naturally convert berberine into dihydroberberine during digestion, suggesting the compound plays a role in berberine's effects even when berberine itself is taken. The field's primary limitation is the near-complete absence of rigorous human clinical trials, and at least one review flagged potential cardiovascular safety considerations related to cardiac ion channel interactions, meaning conclusions about effectiveness and safety in people remain premature.